Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO precision oncology Haslem, D. S., Ji, H. P., Ford, J. M., Nadauld, L. D. 2017; 1
View details for DOI 10.1200/PO.16.00055
View details for PubMedID 32913966
View details for PubMedCentralID PMC7446358